Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): Results of the LENAMAINT trial

Haematologica

Volumn 97, Issue 9, 2012, Pages

  Sockel, Katja ^a   Bornhaeuser, Martin ^a   Mischak Weissinger, Eva ^b   Trenschel, Rudolf ^c   Wermke, Martin ^a   Unzicker, Christian ^d   Kobbe, Guido ^e   Finke, Jürgen ^f   Germing, Ulrich ^e   Mohr, Brigitte ^a   Greiner, Jochen ^g   Beelen, Dietrich ^c   Thiede, Christian ^a   Ehninger, Gerhard ^a   Platzbecker, Uwe ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

^g UNIVERSITY OF ULM   (Germany)

Author keywords

Acute myeloid leukemia; Allogeneic stem cell transplantation; Lenalidomide; Maintenance; Myelodysplastic syndromes

Indexed keywords

CD34 ANTIGEN; LENALIDOMIDE; STEROID; ANTINEOPLASTIC AGENT; THALIDOMIDE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER RELAPSE; CHROMOSOME 5; CHROMOSOME ABERRATION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LETTER; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; FEMALE; GENETICS; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES;

ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 5; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE;

EID: 84865838005     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.067629     Document Type: Letter

References (12)

1. Möllgård L, Saft L, Treppendahl MB, Dybedal I, Nørgaard JM, Astermark J, et al. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Haematologica. 2011;96(7): 963-71
2. van der Straaten HM, van Biezen A, Brand R, Schattenberg AV, Egeler RM, Barge RM, et al. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities. Haematologica. 2005;90(10):1339-45.
3. Ferrant A, Labopin M, Frassoni F, Prentice HG, Cahn JY, Blaise D, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood. 1997;90(8):2931-8.
4. Platzbecker U, Mohr B, von Bonin M, Binder M, Schetelig J, Ehninger G, et al. Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus. Leukemia. 2007;21(11):2384-5.
5. Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012;26(3):381-9
6. Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial Blood. 2011;118(9):2413-9.
7. Lioznov M, El-Cheikh J Jr, Hoffmann F, Hildebrandt Y, Ayuk F, Wolschke C, et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+) and T (HLA-DR(+) cells. Bone Marrow Transplant. 2010;45(2):349-53.
8. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006;108(2):618-21.
9. McDaniel JM, Zou JX, Fulp W, Chen DT, List AF, Epling-Burnette PK. Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation. Leukemia. 2012;26(6): 1425-9.
10. Weissinger EM, Schiffer E, Hertenstein B, Ferrara JL, Holler E, Stadler M, et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2007;109(12):5511-9.
11. Minnema MC, van der Veer M, Aarts T, Emmelot M, Mutis T, Lokhorst HM. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia. 2009;23(3): 605-7.
12. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med. 1992;326(16):1055-8.